BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33781531)

  • 41. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.
    Ru Y; Zhang X; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu Z; Chen S; Ma X; Chen F; Chen J; Wu D
    Bone Marrow Transplant; 2020 Sep; 55(9):1754-1762. PubMed ID: 32066862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.
    Chen S; An L; Han J; Zheng X; Zhang X; Li G; Zhang Y; Cao W; Lv M; Yang D; Jiang E; Pang A; Feng S
    Transpl Immunol; 2023 Oct; 80():101895. PubMed ID: 37414267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
    Marjanska A; Styczynski J
    Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?
    Nelson BP; Nalesnik MA; Bahler DW; Locker J; Fung JJ; Swerdlow SH
    Am J Surg Pathol; 2000 Mar; 24(3):375-85. PubMed ID: 10716151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation.
    Pagliuca S; Bommier C; Michonneau D; Meignin V; Salmona M; Robin M; Prata PH; Xhaard A; de Fontbrune FS; Feghoul L; Dhedin N; de Latour RP; Caillat-Zucman S; Goff JL; Socié G
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2490-2500. PubMed ID: 31421238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
    Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
    Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
    J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolated cerebral post-transplant lymphoproliferative disorder in a lymphoma recipient.
    Tang TC; Chuang WY; Chang H
    J Cancer Res Ther; 2013; 9(3):534-6. PubMed ID: 24126003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical significance of Epstein-Barr Virus detection in the cerebrospinal fluid of patients who underwent hematopoietic stem cell transplantation].
    He Y; Ma R; Wang HF; Mo XD; Zhang YY; Lyu M; Yan CH; Wang Y; Zhang XH; Xu LP; Liu KY; Sun XJ; Huang YQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):737-741. PubMed ID: 38049317
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
    Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
    Dutta R; Miao SY; Phan P; Fernandez-Pol S; Shiraz P; Ho D; Mannis GN; Zhang TY
    J Med Case Rep; 2021 Mar; 15(1):170. PubMed ID: 33773605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.